Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice.

ABSTRACT:

Purpose

Cachexia is a complex syndrome characterized by unintentional weight loss, progressive muscle wasting and loss of appetite. Anti-Fn14 antibody (mAb 002) targets the TWEAK receptor (Fn14) in murine models of cancer cachexia and can extend the lifespan of mice by restoring the body weight of mice. Here, we investigated glucose metabolic changes in murine models of cachexia via [¹⁸F]FDG PET imaging, to explore whether Fn14 plays a role in the metabolic changes that occur during cancer cachexia.

Methods

[¹⁸F]FDG PET/MRI imaging was performed in cachexia-inducing tumour models versus models that do not induce cachexia. SUV_average was calculated for all tumours via volume of interest (VOI) analysis of PET/MRI overlay images using PMOD softw

SUBMITTER: Burvenich IJG 

PROVIDER: S-EPMC11527931 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature